This $436,335 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify novel mechanisms by which antiretroviral antibody responses are generated. The goal is to elucidate the genetic and immunologic basis for retrovirus-neutralizing antibody production, particularly the discovery of an alternative, TLR7-independent pathway for this response. The research will be conducted by the University of Pittsburgh, a major recipient of federal grants and contracts across biomedical research areas. Insights from this study could aid the development of new animal models and therapeutic interventions for viral infections. The project period runs from May 2024 through March 2026.
Generated 3/18/25, 5:22 AM